GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guizhou Yibai Pharmaceutical Co Ltd (SHSE:600594) » Definitions » Capex-to-Revenue

Guizhou Yibai Pharmaceutical Co (SHSE:600594) Capex-to-Revenue : 0.01 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Guizhou Yibai Pharmaceutical Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Guizhou Yibai Pharmaceutical Co's Capital Expenditure for the three months ended in Mar. 2025 was ¥-6.67 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥501.48 Mil.

Hence, Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue for the three months ended in Mar. 2025 was 0.01.


Guizhou Yibai Pharmaceutical Co Capex-to-Revenue Historical Data

The historical data trend for Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhou Yibai Pharmaceutical Co Capex-to-Revenue Chart

Guizhou Yibai Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.13 0.12 0.05 0.04

Guizhou Yibai Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.06 0.01

Competitive Comparison of Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue falls into.


;
;

Guizhou Yibai Pharmaceutical Co Capex-to-Revenue Calculation

Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-96.321) / 2174.032
=0.04

Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-6.671) / 501.481
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guizhou Yibai Pharmaceutical Co  (SHSE:600594) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Guizhou Yibai Pharmaceutical Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guizhou Yibai Pharmaceutical Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Guizhou Yibai Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 220-1 Baiyun Avenue, Guiyang, Guizhou, CHN, 550008
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
Executives
Dou Qi Ling Director
Gan Ning Director
Lang Hong Ping Director
Xia Xiao Hui senior management
Dou Ya Qi Director
Wang Zhi Wei Director
Zhu Yue Xing Director
Dai Yuan Fu senior management
Zhang Sheng Gui senior management
Feng Zhi Gang senior management
Yue Wei Director
Liu Hua Supervisors
Ye Xiang Wu Director
Jian Wei Guang Director

Guizhou Yibai Pharmaceutical Co Headlines

No Headlines